Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

The lack of an efficient anti-tumor T cell response contributes to the failure of anti-PD1 therapy. Here, the authors show a potential strategy to improve the therapeutic effects of anti-PD-1 antibody by simultaneously targeting IL-21 to tumor-reactive T cells in vivo.

Saved in:
Bibliographic Details
Main Authors: Ying Li, Yanni Cong, Mingming Jia, Qianqian He, Haiqing Zhong, Yun Zhao, Hang Li, Meining Yan, Jia You, Jia Liu, Lieping Chen, Haiying Hang, Shengdian Wang
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Science
Q
Online Access:https://doaj.org/article/e0144328845a498a9c1f543f87d37f7c
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The lack of an efficient anti-tumor T cell response contributes to the failure of anti-PD1 therapy. Here, the authors show a potential strategy to improve the therapeutic effects of anti-PD-1 antibody by simultaneously targeting IL-21 to tumor-reactive T cells in vivo.

Similar Items